Skip to main content

Author: Customer Service

PrimeEnergy Resources Corporation Reports Second Quarter and First Half 2026 Results

HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) — PrimeEnergy Resources Corporation (NASDAQ: PNRG) (“PrimeEnergy” or the “Company”) today reported financial and operating results for the three and six months ended June 30, 2026. PrimeEnergy reported second quarter 2026 net income of $6.5 million, or $4.06 per basic share, compared with $3.2 million, or $1.94 per basic share, for the second quarter of 2025. For the first six months of 2026, net income was $10.9 million, or $6.72 per basic share, compared with $12.4 million, or $7.37 per basic share, for the first six months of 2025. Second quarter results reflected strong oil prices offset in part by significantly negative natural gas prices in the Permian Basin. The Company realized an average oil price of $98.85 per barrel, compared with $56.96 per barrel in the second quarter of 2025,...

Continue reading

QuoteMedia Reports 11% Revenue Growth for Q2 2026

PHOENIX, Aug. 14, 2026 (GLOBE NEWSWIRE) — QuoteMedia, Inc. (OTCQB: QMCI), a provider of financial market data and technology solutions, today announced financial results for the quarter ended June 30, 2026. Revenue increased 11% to $5.45 million, compared with $4.93 million for the same period in 2025. For more than two decades, QuoteMedia has focused on becoming the market data and technology partner financial institutions can rely on for comprehensive solutions, responsive service and compelling value. Today, banks, brokerage firms, wealth managers, private equity firms and other financial organizations are increasingly seeking flexible, cost-effective alternatives to traditional market data providers. QuoteMedia addresses that demand through a broad suite of streaming market data feeds, XML/JSON APIs, financial content and analytics,...

Continue reading

Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SAN DIEGO, Aug. 14, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that it has entered into a definitive securities purchase agreement with institutional investors for the purchase and sale of 4,379,581 shares of the Company’s common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof), at a price of $1.37 per share of common stock (or $1.3699 per pre-funded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. Each pre-funded warrant will be exercisable upon issuance at an exercise price of $0.0001 per share and will expire when exercised in full. In addition, in a concurrent private placement, the Company...

Continue reading

Track Group Reports 3rd Quarter Fiscal 2026 Financial Results

Key Third Quarter Data PointsRevenue of $9.09 million, was roughly flat vs. $9.09 million last year. Growth in our recurring monitoring and services revenue was offset by the delay of a product sale to a long-standing middle eastern customer due to ongoing regional conflict. Sales in the prior comparable period to this customer created a tough comparison. We still expect this order to materialize in the future.Monitoring and other related service revenue of $8.51 million, increased 5.5% from $8.07 million last year. The increase was predominantly driven by business growth in Florida.Net income attributable to shareholders of $22.44 million, increased 1,465% from $1.43 million last year. This was driven primarily by the gain of $23.46 million related to the recent discounted settlement of our previous long-term debt.13Net income...

Continue reading

PCS Edventures! Announces Results for the First Quarter of Fiscal Year 2027

MERIDIAN, Idaho, Aug. 14, 2026 (GLOBE NEWSWIRE) — PCS Edventures!, Inc. (“PCSV”), a leading provider of TK-12 Science, Technology, Engineering and Mathematics (“STEM”) education programs, today announced results of operations for its first quarter of fiscal year 2027, which ended on June 30, 2026. First Quarter 2027 Overview:Revenue decreased 28.2% to $1.74 million in the first quarter of fiscal year 2027 compared to the first quarter in the previous year Gross margin decreased 60 basis points to 62.8% in the first quarter of fiscal year 2027 compared to the first quarter in the previous year. Net income before income tax provision was $0.10 million in the first quarter versus $0.60 million in the previous year same quarter. Cash on hand decreased 1.0% to $2.65 million versus the balance at the beginning of the fiscal year. During...

Continue reading

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders  Completed a concurrent PIPE financing raising $132 million in gross proceeds REDWOOD CITY, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended June 30, 2026, and provided a corporate update. “We are excited to unite Jasper Therapeutics and Kira Pharmaceuticals to advance our shared mission of developing a differentiated portfolio of innovative therapies for patients with significant immune-mediated diseases. Supported by our recent $132...

Continue reading

Strata Biotech Labs, LLC Earns NSF/ANSI 455-2 Dietary Supplement GMP Certification

Independent certification from global human health organization NSF demonstrates a commitment to personal care product quality and compliance with U.S. GMP requirementsDr Christina Rahm / Strata Biotech LabDr. Christina Rahm, Founder of Strata Biotech Labs, at the company’s NSF/ANSI 455-2 GMP-certified manufacturing facility in Las Vegas, Nevada.Las Vegas, Nevada, Aug. 14, 2026 (GLOBE NEWSWIRE) — Strata Biotech Labs, LLC’s manufacturing facility in Las Vegas, Nevada, was recently added to NSF’s NSF/ANSI 455-2 Dietary Supplements Good Manufacturing Practice (GMP) certification. Earning GMP certification from NSF verifies that a manufacturing facility has the proper methods, equipment, facilities and controls in place to produce dietary supplement products. Strata Biotech Labs’ facility at 6320 McLeod Drive, Suite 1, Las...

Continue reading

JP 3E Holdings, Inc. Appoints Henry Ji, Ph.D., Stephen Ma and Jaedong Yoon to Board of Directors

Appointments strengthen JP 3E Holdings’ capital markets, public-company leadership and cross-border capabilities as the Company advances its strategic metals and real-world-asset initiatives TRENTON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) — JP 3E Holdings, Inc. (OTC Markets: JPTE) (“JP 3E Holdings” or the “Company”) today announced the appointment of Henry Ji, Ph.D., Stephen Ma and Jaedong Yoon to its Board of Directors, effective August 13, 2026. The appointments strengthen JP 3E Holdings’ Board with additional experience across public-company leadership, capital markets, life sciences, institutional finance and U.S.-Korea cross-border business. The expanded Board will support JP 3E Holdings as the Company advances its strategic initiatives, including its activities in strategic metals and real-world-asset...

Continue reading

Vislink Reports Second Quarter 2026 Financial Results

Company Delivers Second Consecutive Quarter of Positive EBITDA; Non-GAAP EBITDA Profit of $0.1 Million vs. ($1.9 Million) Loss in Prior Year Quarter Q2 Revenue of $5.9 Million Increases 22.6% Year-Over-Year and 9.7% Sequentially H1 2026 Revenue of $11.3 Million Increases 19.6% Year-Over-Year Operating Expenses Decline 36.0% Year-Over-Year Continued investment in R&D and Business Development in the Defense Sector MT. OLIVE, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) — Vislink Technologies, Inc. (“Vislink” or the “Company”) (OTCID: VISL), a global leader in real-time video communications for the defense, public safety, and broadcast markets, today reported financial and operational results for the second quarter and six months ended June 30, 2026. CEO Commentary “Vislink delivered its second consecutive quarter of positive EBITDA in...

Continue reading

UPAY Inc. Launches Petra Software Website

DALLAS, Aug. 14, 2026 (GLOBE NEWSWIRE) — UPAY Inc. (“UPAY” or the “Company”) (OTCQB: UPYY), a technology-focused company with interests in fintech, compliance, software platforms and related digital services, today announced the launch of the Petra Software website at www.petra.software. The new website describes Petra Software’s software development services and the markets in which it intends to operate. The launch forms part of UPAY’s strategy to position Petra Software as a dedicated software development and technology partner serving the UPAY group and, over time, third-party clients in South Africa, the United States and other international markets. As of the date of this press release, Petra Software derives substantially all of its revenue from services provided to members of the UPAY group and has not entered...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.